Procyon Advisors LLC Purchases 12,841 Shares of Boston Scientific Corporation $BSX

Procyon Advisors LLC increased its holdings in Boston Scientific Corporation (NYSE:BSX) by 318.1% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 16,878 shares of the medical equipment provider’s stock after buying an additional 12,841 shares during the period. Procyon Advisors LLC’s holdings in Boston Scientific were worth $1,609,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the 2nd quarter valued at about $26,000. Steph & Co. bought a new position in shares of Boston Scientific in the third quarter worth approximately $25,000. Murphy & Mullick Capital Management Corp raised its stake in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares in the last quarter. Financial Consulate Inc. purchased a new stake in Boston Scientific in the third quarter valued at approximately $25,000. Finally, United Community Bank lifted its position in Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 147 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $69.54 on Monday. Boston Scientific Corporation has a 52-week low of $67.56 and a 52-week high of $109.50. The stock has a market capitalization of $103.34 billion, a price-to-earnings ratio of 35.84, a price-to-earnings-growth ratio of 0.97 and a beta of 0.69. The company has a fifty day moving average of $79.74 and a 200-day moving average of $91.94. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm’s revenue was up 15.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Needham/analyst support — Needham & Company maintained a Buy rating and $97 price target, arguing the financial fallout from the Accolade pacemaker recalls is limited and supports a continued Buy stance. Boston Scientific: Limited Financial Fallout From Pacemaker Recalls Supports Continued Buy Rating
• Neutral Sentiment: Stifel trims target but keeps Buy — Stifel cut its price target from $110 to $90 while retaining a Buy rating, reducing upside expectations even as the firm remains constructive. Benzinga: Stifel Nicolaus Price Target
• Neutral Sentiment: Other firms lower expectations — Truist and UBS have lowered price targets/expectations (Truist to $92), signaling more cautious analyst views on near-term growth despite mixed analyst conviction. Truist Lowers Boston Scientific Price Target to $92
• Negative Sentiment: Multiple securities class-action alerts — Several law firms have filed or are soliciting lead plaintiffs for securities fraud suits tied to disclosures covering July 2025–Feb 2026; reminders and deadlines (May 4, 2026) are fueling legal uncertainty and potential future liability. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: NYT report alleges long-standing battery issues — The New York Times reports Boston Scientific was aware of pacemaker battery problems for years, a story that raises reputational and regulatory risk beyond the company’s stated scope. Boston Scientific Knew of Pacemaker Battery Problems for Years
• Negative Sentiment: Recall expanded — Market chatter notes Boston Scientific amended its Accolade pacemaker recall, increasing the affected population to ~1.6 million devices, which raises potential remediation costs and investor concern. Market Chatter: Boston Scientific Amends Recall of Accolade Pacemakers, Affected Population Now 1.6 Million
• Negative Sentiment: High-profile criticism — Jim Cramer publicly criticized BSX’s recent performance and competitive pressures, a sentiment that can influence retail flows and short-term sentiment. Jim Cramer on Boston Scientific: “This Stock Was One of the Greatest Performers, It’s Not Anymore”

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. TD Cowen decreased their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. Barclays dropped their price objective on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a report on Tuesday, February 3rd. Robert W. Baird cut their target price on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Weiss Ratings cut Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, February 4th. Finally, Citigroup dropped their price target on Boston Scientific from $102.00 to $94.00 and set a “buy” rating for the company in a research note on Wednesday, March 11th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $106.27.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.